Grant: Project Grant
Ottawa Hospital Research Institute
$738,225.00
A therapeutic strategy for PTEN tumour suppressor restoration in glioblastoma
FY 2021-22
Summary
Glioblastoma is an aggressive type of brain cancer that kills hundreds of Canadians every year. The current treatments (surgery, radiation and chemotherapy) only give small improvements in patient survival. We are proposing to test a new therapeutic strategy. This aims to "repair" a common, acquired genetic defect that causes glioblastoma. We will determine how well this strategy works on its own and in combination with existing therapies.
Initially the strategy will be tested in cultured cancer cells that we isolate from
glioblastoma patients. We will then test the strategy in animal models; in these, we grow the patient cells in mice in a way that closely mimics the way this cancer behaves in humans. These experiments will determine if this method should go on to testing in clinical trials.
Department
Program
Project Grant
Recipient
Location
Ontario, Canada
Recipient Type
Other
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
452003
Name
Lorimer Ian Anthony J
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Progression & Therapeutics
Projecttitle
A therapeutic strategy for PTEN tumour suppressor restoration in glioblastoma
Programtype2
Operating Grants
Orgnameinp2
Ottawa Hospital Research Institute
Cihramount2
$738,225
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Biotherapeutics; Cell-Mediated Therapy; Glioblastoma; Pten
Abstract
Glioblastoma is an aggressive type of brain cancer that kills hundreds of Canadians every year. The current treatments (surgery, radiation and chemotherapy) only give small improvements in patient survival. We are proposing to test a new therapeutic strategy. This aims to "repair" a common, acquired genetic defect that causes glioblastoma. We will determine how well this strategy works on its own and in combination with existing therapies.
Initially the strategy will be tested in cultured cancer cells that we isolate from
glioblastoma patients. We will then test the strategy in animal models; in these, we grow the patient cells in mice in a way that closely mimics the way this cancer behaves in humans. These experiments will determine if this method should go on to testing in clinical trials.
Competitiondate
202109
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Lorimer, Ian Anthony J
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $738,225~ $0~